According to the third quarterly report of Jinhe Biology in 2021, the company's main income was 1.439 billion yuan, up 19.21% from the same period last year; the net profit was 125 million yuan, up 22.96% from the same period last year; and the non-net profit was 98.606 million yuan, up 3.34% from the same period last year. Among them, in the third quarter of 2021, the company's main income in a single quarter was 478 million yuan, up 33.26% from the same period last year; and the net profit in a single quarter was 7.8624 million yuan, up 13.43% from the same period last year. The non-net profit in a single quarter was 6.2976 million yuan, up 79.84% from the same period last year; the debt ratio was 32.32%, the financial expenses was 46.4916 million yuan, and the gross profit margin was 33.7%.
There are one new top ten tradable shareholders in this period, Inner Mongolia Mengjili Economic and technological Development Co., Ltd. holds 1.94 million shares, accounting for 0.31% of tradable shares; a total of 2 shareholders increase their holdings, Inner Mongolia Jinhe Holdings Co., Ltd. increased its shareholding by 137.75867 million shares. The shareholder's shareholding accounted for 38.95% of tradable shares, while Wang Liangang increased its shareholding of 107800 shares, accounting for 0.38% of tradable shares. A total of 2 shareholders reduced their holdings, Hohhot Changfuxing Investment Management Company (Limited Partnership) reduced its holdings of 500000 shares, accounting for 1.22% of the outstanding shares, and the asset management plan of Shanghai Bank Fund-Pudong Development Bank-Shanghai Bank Fund Fortune 51 reduced its holdings by 421000 shares. the shareholder accounts for 1.02% of the outstanding shares.
For a summary of the financial report data, please see the following figure:
This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If there are any questions in the article, please contact us.